信立泰(002294.SZ)：SAL0150片临床试验申请获受理

Core Viewpoint - The company, Sinopharm (002294.SZ), has received a notice of acceptance from the National Medical Products Administration for its clinical trial application of the innovative drug SAL0150, aimed at treating type 2 diabetes and its complications, as well as obesity or overweight conditions [1] Group 1 - The clinical trial application for SAL0150 has been officially accepted [1] - SAL0150 is developed independently by the company [1] - The application targets type 2 diabetes and its complications, along with obesity or overweight [1]